Critically, CCT3833 induces tumor cell death and elicits therapeutic efficacy at well-tolerated doses in mice, and it is evaluated in patients in a phase I clinical trial, achieving a proof-of-concept unconfirmed clinical response in a patient with aggressive KRAS-mutant spindle cell sarcoma who was not eligible for other treatments. Here, KRAS is linked to neoplasm.